Mandate

Vinge advises Isofol in connection with its listing on Nasdaq Stockholm

Vinge has advised Isofol Medical AB in connection with its listing on Nasdaq Stockholm, with the first day of trading on 21 October 2021. The prospectus was approved by the Swedish Financial Supervisory Authority on 18 October 2021. Isofol has a market value corresponding to approximately SEK 1.5 billion.

Isofol is a biotech company in late clinical phase which develops arfolitixorin in order to improve standard treatment of 5-FE based chemotherapy, primarily for advanced colorectal cancer, by increasing tumour response and progression free survival.

Vinge’s team primarily consisted of Anders StridJenny Sandlund and Edin Agic (Capital Markets), Victor Ericsson and Emelie Svanberg (Tax), Anna Ståhlklo (Commercial Agreements), Alexander Lindeberg (IP) and Rebecka Hansson (Employment Law).

Related

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025